- Home
- SYT vs LEXX Comparison
SYT vs LEXX Comparison
Compare SYT & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYT
- LEXX
- Stock Information
- Founded
- SYT 2010
- LEXX 2004
- Country
- SYT Japan
- LEXX Canada
- Employees
- SYT N/A
- LEXX N/A
- Industry
- SYT Real Estate
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- SYT Finance
- LEXX Health Care
- Exchange
- SYT Nasdaq
- LEXX Nasdaq
- Market Cap
- SYT 41.2M
- LEXX 39.1M
- IPO Year
- SYT 2023
- LEXX N/A
- Fundamental
- Price
- SYT $1.64
- LEXX $1.90
- Analyst Decision
- SYT
- LEXX Strong Buy
- Analyst Count
- SYT 0
- LEXX 2
- Target Price
- SYT N/A
- LEXX $11.00
- AVG Volume (30 Days)
- SYT 29.0K
- LEXX 249.7K
- Earning Date
- SYT 03-05-2025
- LEXX 01-10-2025
- Dividend Yield
- SYT 0.43%
- LEXX N/A
- EPS Growth
- SYT N/A
- LEXX N/A
- EPS
- SYT 0.08
- LEXX N/A
- Revenue
- SYT $149,124,408.00
- LEXX $496,923.00
- Revenue This Year
- SYT N/A
- LEXX $20.39
- Revenue Next Year
- SYT N/A
- LEXX $113.25
- P/E Ratio
- SYT $20.62
- LEXX N/A
- Revenue Growth
- SYT 3.11
- LEXX 77.63
- 52 Week Low
- SYT $1.18
- LEXX $1.36
- 52 Week High
- SYT $6.10
- LEXX $6.85
- Technical
- Relative Strength Index (RSI)
- SYT 46.89
- LEXX 37.49
- Support Level
- SYT $1.18
- LEXX $1.62
- Resistance Level
- SYT $1.66
- LEXX $2.25
- Average True Range (ATR)
- SYT 0.17
- LEXX 0.24
- MACD
- SYT -0.04
- LEXX -0.03
- Stochastic Oscillator
- SYT 49.46
- LEXX 34.57
About SYT SYLA Technologies Co. Ltd.
SYLA Technologies Co Ltd is a property technology company. It provides asset management platform systems that facilitate real estate crowd-funding as well as the purchase and sale of real estate.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.